Skip to main content

Cardiff Oncology, Inc.

CRDF
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001213037

In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Cardiff Oncology, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of CRDF: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders53156+4
Shares5.99M15.39M−606.7K (−10.1%)
Value$8.81M$2$7.58M−$1.22M (−13.9%)

1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Cardiff Oncology, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to CRDF in Q3 2023
InstitutionSharesValue% of portfolio
MAI Capital Management224,749$312.4K0.00%
Man Group plc–$98.2K0.00%
Two Sigma Securities, LLC19,985$27.8K0.00%
Simplex Trading, LLC15,551$21.0K0.00%
Moser Wealth Advisors, LLC806$1.12K0.00%
Tower Research Capital LLC (TRC)360$5000.00%
Qube Research & Technologies Ltd52$720.00%
Cornerstone Planning Group LLC5$70.00%

Sold out (4)

Institutions that held Cardiff Oncology, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of CRDF in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Citadel Advisors LLC86,123$126.6K
Millennium Management LLC48,739$71.6K
NewSquare Capital LLC125$184
Sofos Investments, Inc.1$2

Not filed for Q3 2023 yet (1)

Institutions that held Cardiff Oncology, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CRDF in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
BerganKDV Wealth Management, LLC1$2